Denali Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good morning. I'm Salveen Richter. Thanks for joining us. I'm the biotechnology analyst at Goldman Sachs. And with us, we're really pleased to have Denali and Ryan Watts, the CEO.
Brian, thanks so much for being here. And to start, could you just remind us of the clinical data that is expected across your portfolio for the remainder of this year? And as we look to next year, in what you are most focused on?
Questions & Answers
Salveen, grateful -- really grateful to be here and thank you for the invitation. It's exciting to be with you at such an exciting time in neurodegeneration drug discovery and research, I think we're on the cusp of, I think, really important medicines for patients.
And so you asked about what to expect from Denali in the next 6 to 12 months. And let me just start by saying we have 5 clinical stage programs across different therapeutic areas and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |